Study #2022-0955
A phase 1/2, open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of oral TP-3654 in patients with intermediate or high-risk primary or secondary myelofibrosis
MD Anderson Study Status
Enrolling
Treatment Agent
Nusivertib, Ruxolitinib, Momelotinib
Description
This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Myelofibrosis
Study phase:
Physician name:
Prithviraj Bose
Department:
Leukemia
For general questions about clinical trials:
1-866-419-2881
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.